Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K W Perry

Showing results (81-90 of 115) with videos related to

Pageof 12
Sort By:
Research Communications in Chemical Pathology and Pharmacology|January 1, 1986
1-(1-Naphthyl)piperazine, a central serotonin agonistR W Fuller, N R Mason, H D Snoddy, et al.
European Journal of Pharmacology|September 11, 1981
Ionophore (A23187)-induced efflux of [3H]norepinephrine and endogenous norepinephrine in the rat vas deferensM L Cohen, A S Landry, K W Perry, et al.
Archives Internationales De Pharmacodynamie Et De Therapie|April 1, 1974
Effect of phenobarbital on the metabolism and serotonin-depleting action of 4-chloro-beta, beta-difluoroamphetamine in ratsR W Fuller, J C Baker, K W Perry, et al.
The Journal of Pharmacy and Pharmacology|April 1, 1985
Pergolide elevation of MHPG sulphate concentration in rat hypothalamus blocked by spiperone and mimicked by other dopamine agonistsR W Fuller, S K Hemrick-Luecke, K W Perry, et al.
Brain Research. Developmental Brain Research|November 19, 1993
Ontogenetic SKF 38393 treatments sensitize dopamine D1 receptors in neonatal 6-OHDA-lesioned ratsL Gong, R M Kostrzewa, R Brus, et al.
Psychopharmacology|March 1, 1996
Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in ratsF P Bymaster, S K Hemrick-Luecke, K W Perry, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1997
Persistent spontaneous oral dyskinesias in haloperidol-withdrawn rats neonatally lesioned with 6-hydroxydopamine: absence of an association with the Bmax for [3H]raclopride binding to neostriatal homogenatesN Y Huang, R M Kostrzewa, C Li, et al.
Journal of Neurochemistry|August 11, 2000
The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving ratJ Cartmell, K W Perry, C R Salhoff, et al.
Brain Research Bulletin|January 1, 1994
Proposed animal model of attention deficit hyperactivity disorderR M Kostrzewa, R Brus, J H Kalbfleisch, et al.
Neuropharmacology|May 30, 2001
Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockadeJ Cartmell, K W Perry, C R Salhoff, et al.
Pageof 12

Showing results (81-90 of 115) with videos related to

Sort By:
Pageof 12
Research Communications in Chemical Pathology and Pharmacology|January 1, 1986
1-(1-Naphthyl)piperazine, a central serotonin agonistR W Fuller, N R Mason, H D Snoddy, et al.
European Journal of Pharmacology|September 11, 1981
Ionophore (A23187)-induced efflux of [3H]norepinephrine and endogenous norepinephrine in the rat vas deferensM L Cohen, A S Landry, K W Perry, et al.
Archives Internationales De Pharmacodynamie Et De Therapie|April 1, 1974
Effect of phenobarbital on the metabolism and serotonin-depleting action of 4-chloro-beta, beta-difluoroamphetamine in ratsR W Fuller, J C Baker, K W Perry, et al.
The Journal of Pharmacy and Pharmacology|April 1, 1985
Pergolide elevation of MHPG sulphate concentration in rat hypothalamus blocked by spiperone and mimicked by other dopamine agonistsR W Fuller, S K Hemrick-Luecke, K W Perry, et al.
Brain Research. Developmental Brain Research|November 19, 1993
Ontogenetic SKF 38393 treatments sensitize dopamine D1 receptors in neonatal 6-OHDA-lesioned ratsL Gong, R M Kostrzewa, R Brus, et al.
Psychopharmacology|March 1, 1996
Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in ratsF P Bymaster, S K Hemrick-Luecke, K W Perry, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 1997
Persistent spontaneous oral dyskinesias in haloperidol-withdrawn rats neonatally lesioned with 6-hydroxydopamine: absence of an association with the Bmax for [3H]raclopride binding to neostriatal homogenatesN Y Huang, R M Kostrzewa, C Li, et al.
Journal of Neurochemistry|August 11, 2000
The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving ratJ Cartmell, K W Perry, C R Salhoff, et al.
Brain Research Bulletin|January 1, 1994
Proposed animal model of attention deficit hyperactivity disorderR M Kostrzewa, R Brus, J H Kalbfleisch, et al.
Neuropharmacology|May 30, 2001
Acute increases in monoamine release in the rat prefrontal cortex by the mGlu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockadeJ Cartmell, K W Perry, C R Salhoff, et al.
Pageof 12